BIOPHYTIS (EPA:ALBPS) - Biophytis to host virtual KOL event on Sarconeos (BIO101) on its lead projects in COVID-19 and Sarcopenia

Transparency directive : regulatory news

06/10/2021 08:00

Press release

Biophytis to host virtual KOL event on Sarconeos (BIO101) on its lead projects
in COVID-19 and Sarcopenia

Paris, France, Cambridge (Massachusetts, United States), October 6, 2021 8am
CET - Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a
clinical-stage biotechnology company focused on the development of therapeutics
that slow the degenerative processes associated with aging and improve
functional outcomes for patients suffering from age-related diseases, including
severe respiratory failure in patients suffering from COVID-19, today announces
it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on
its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and
Sarcopenia .

The webinar will feature a presentation by four KOLs including:
* For the COVA study with Sarconeos (BIO101) in COVID-19:
o Professor Suzana Margareth Ajeje Lobo, MD, Hospital de Base Da Faculdade de
Medicina de São José Do Rio Preto, São Paulo State, Brazil
o Dr Girish Balachandran Nair, MD, Associate Professor of Medicine in the
division of Pulmonary and Critical Care, Medical Director of the Interstitial
Lung Disease (ILD) program and the Associate Program Director for the Pulmonary
and Critical Care Fellowship at Beaumont Hospital in Royal Oak, USA
* For the SARA study with Sarconeos (BIO101) in Sarcopenia:
o Professor Bruno Vellas, MD, PhD, Chair of the Gerontopole at the University
of Toulouse in France
o Dr Roger A. Fielding, Ph.D., Associate Center Director, Jean Mayer USDA Human
Nutrition Research Center on Aging at Tufts University, Director and Senior
Scientist, Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Professor
of Nutrition and Medicine, Friedman School of Nutrition Science and Policy,
Tufts University School of Medicine as well as Associate Director, Boston
Claude D. Pepper Older Americans Independence Center Boston, MA

The virtual event will take place on October 6th, 2021, from 5:30pm to 7:30pm
CET, with two distinct sessions: COVA/COVID-19 and then SARA/Sarcopenia. In
order to register for the event, please click here.

The first session will be dedicated to the COVA project in COVID-19:
* Time: 5:30 to 6:15pm
* KOLs: Prof Girish Nair (USA) and Dr Suzanna Lobo (Brazil)
* Biophytis representatives: Stanislas Veillet (CEO), Evelyne Nguyen (CFO) and
Rob Van Maanen (CMO)

The second session will be dedicated to the SARA project in Sarcopenia:

* Time: 6:45 to 7:30pm
* KOLs: Pr
* Bruno Vellas (France) and Dr Roger A. Fielding (USA)
* Biophytis representatives: Stanislas Veillet (CEO), Evelyne Nguyen (CFO) and
Jean Mariani (Scientific Board Director)

About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19. Sarconeos (BIO101), our leading drug
candidate, is a small molecule, administered orally, in development for the
treatment of sarcopenia in a Phase 2 clinical trial in the United States and
Europe (SARA-INT). It is also being studied, in a clinical two-part Phase 2-3
study (COVA) for the treatment of severe respiratory manifestations of COVID-19
in Europe, Latin America, and the US. A pediatric formulation of Sarconeos
(BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy
(DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The
company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN:
FR0012816825) and ADSs (American Depositary Shares) are listed on Nasdaq
Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information visit
www.biophytis.com

Disclaimer
This press release contains forward-looking statements. Forward-looking
statements include all statements that are not historical facts. In some cases,
you can identify these forward- looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues," "may," "will,"
"should," "could," "seeks," "predicts," "intends," "trends," "plans,"
"estimates," "anticipates" or the negative version of these words or other
comparable words. Such forward-looking statements are based on assumptions that
Biophytis considers to be reasonable. However, there can be no assurance that
the statements contained in such forward-looking statements will be verified,
which are subject to various risks and uncertainties. The forward-looking
statements contained in this press release are also subject to risks not yet
known to Biophytis or not currently considered material by Biophytis.
Accordingly, there are or will be important factors that could cause actual
outcomes or results to differ materially from those indicated in these
statements. Please also refer to the "Risk and uncertainties the Company is to
face" section from the Company's 2020 Annual Report available on BIOPHYTIS
website (www.biophytis.com) and as exposed in the "Risk Factors" section of
form 20-F as well as other forms filed with the SEC (Securities and Exchange
Commission, USA). We undertake no obligation to publicly update or review any
forward- looking statement, whether as a result of new information, future
developments or otherwise, except as required by law.

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
Investors@biophytis.com

Media contact
Life Sci Advisors
Sophie Baumont
E: sophie@lifesciadvisors.com
T: +33 6 27 74 74 49

BIOPHYTIS's latest news

24/04/2024 23:00

BIOPHYTIS (EPA:ALBPS) - Biophytis to host virtual KOL event on Sarconeos (BIO101) on its lead projects in COVID-19 and Sarcopenia

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories